Search Filters

Search Results

Found 1 results

510(k) Data Aggregation

    K Number
    K062284
    Device Name
    CES ULTRA
    Manufacturer
    Date Cleared
    2007-04-05

    (241 days)

    Product Code
    Regulation Number
    882.5800
    Reference & Predicate Devices
    Why did this record match?
    Applicant Name (Manufacturer) :

    NEURO-FITNESS LLC

    AI/MLSaMDIVD (In Vitro Diagnostic)TherapeuticDiagnosticis PCCP AuthorizedThirdpartyExpeditedreview
    Intended Use

    The CES Ultra is indicated for the treatment of insomnia. depression or anxiety.

    Device Description

    The CES Ultra is a device designed to deliver therapeutic electrical and stimulation for cranial electrotherapy stimulation (CES) applications. The stimulator is powered by a standard 9-volt alkaline battery and delivers a single channel of low-level, constant current electrical stimulation to electrodes connected to the patient's skin via conductive lead wires. Stimulation current is applied to the patient via either standard self-adhering conductive electrodes placed on the head or conductive clip-type electrodes attached to the patient's ear lobes. The stimulator's user controls include: a rotary stimulation amplitude control which allows user adjustment of stimulation current and includes an integral power on/off switch; and a pushbutton timer selector switch which allows user selection of either continuous stimulation or timed stimulation sessions with automatic stimulation shut-off.

    AI/ML Overview

    The provided text is a 510(k) summary for the CES Ultra™ Stimulator, which is a Cranial Electrotherapy Stimulator (CES). Based on the information provided, no specific acceptance criteria or a study proving the device meets those criteria were required or conducted for this 510(k) submission.

    Here's a breakdown of why and what information is available based on your requested points:

    1. A table of acceptance criteria and the reported device performance

    Acceptance CriteriaReported Device Performance
    Not ApplicableNot Applicable

    Reasoning: The document explicitly states: "Neither nonclinical nor clinical testing was required to demonstrate the substantial equivalence of the CES Ultra to the designated predicate devices." This means no specific performance criteria linked to clinical outcomes were set for this submission. The basis for clearance was substantial equivalence to already marketed devices.

    2. Sample sized used for the test set and the data provenance (e.g. country of origin of the data, retrospective or prospective)

    • Sample Size for Test Set: Not applicable, as no clinical or nonclinical testing was required or conducted to demonstrate substantial equivalence against specific performance criteria.
    • Data Provenance: Not applicable.

    3. Number of experts used to establish the ground truth for the test set and the qualifications of those experts (e.g. radiologist with 10 years of experience)

    • Not applicable, as no clinical or nonclinical testing was required or conducted.

    4. Adjudication method (e.g. 2+1, 3+1, none) for the test set

    • Not applicable, as no clinical or nonclinical testing was required or conducted.

    5. If a multi reader multi case (MRMC) comparative effectiveness study was done, If so, what was the effect size of how much human readers improve with AI vs without AI assistance

    • No MRMC study was done. The device is a direct therapeutic device (Cranial Electrotherapy Stimulator), not an AI-assisted diagnostic or interpretation tool for human readers.

    6. If a standalone (i.e. algorithm only without human-in-the-loop performance) was done

    • Yes, in spirit, the substantial equivalence determination is a form of standalone evaluation. The FDA reviewed the device's technological characteristics (frequency, pulse width, amplitude) and compared them to those of legally marketed predicate devices to determine that the CES Ultra was "substantially equivalent." This means the device itself, based on its design and parameters, was deemed equivalent without needing a human-in-the-loop study.

    7. The type of ground truth used (expert consensus, pathology, outcomes data, etc)

    • Ground Truth Type: The ground truth for this submission was the established safety and effectiveness of the predicate devices (NF-1 Mindpeace CES, K895175, and HP-1 Healthpax CES, K883812). The "ground truth" for the CES Ultra's substantial equivalence was that its stimulation parameters (frequency, pulse width, and amplitude) were "well within the established range of such parameters that are generally accepted as safe and effective for CES" as demonstrated by the predicate devices.

    8. The sample size for the training set

    • Not applicable. This device is not an AI/ML algorithm that requires a training set in the conventional sense. The "training" here refers to existing knowledge about CES devices from prior marketing clearances.

    9. How the ground truth for the training set was established

    • Not applicable in the context of an AI/ML training set. The "ground truth" for establishing substantial equivalence was based on the prior regulatory clearances and established safety and effectiveness of the predicate CES devices. These predicates had previously gone through their own approval processes, which may have involved clinical studies or other data to establish their safety and effectiveness. The CES Ultra leveraged this existing "ground truth" by demonstrating its similarity to these already-approved devices.
    Ask a Question

    Ask a specific question about this device

    Page 1 of 1